Amgen Inc. $AMGN Position Reduced by Bank of New York Mellon Corp

Bank of New York Mellon Corp cut its position in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,907,016 shares of the medical research company’s stock after selling 72,170 shares during the quarter. Bank of New York Mellon Corp’s holdings in Amgen were worth $1,278,805,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of AMGN. Brighton Jones LLC lifted its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after buying an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC lifted its stake in Amgen by 10.6% during the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after buying an additional 114 shares in the last quarter. Schnieders Capital Management LLC. lifted its position in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares in the last quarter. Main Street Financial Solutions LLC lifted its position in shares of Amgen by 11.3% in the second quarter. Main Street Financial Solutions LLC now owns 4,086 shares of the medical research company’s stock worth $1,141,000 after purchasing an additional 416 shares in the last quarter. Finally, Ieq Capital LLC lifted its position in shares of Amgen by 5.1% in the second quarter. Ieq Capital LLC now owns 54,152 shares of the medical research company’s stock worth $15,120,000 after purchasing an additional 2,611 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the transaction, the senior vice president owned 7,009 shares in the company, valued at $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.85% of the stock is currently owned by company insiders.

Amgen Trading Down 0.3%

NASDAQ:AMGN opened at $328.26 on Wednesday. The stock’s 50 day moving average price is $342.12 and its 200 day moving average price is $345.42. Amgen Inc. has a 52 week low of $267.83 and a 52 week high of $391.29. The company has a market capitalization of $177.17 billion, a P/E ratio of 22.84, a P/E/G ratio of 3.30 and a beta of 0.42. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to the consensus estimate of $8.58 billion. During the same quarter in the prior year, the company posted $4.90 earnings per share. The firm’s revenue was up 5.8% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, research analysts forecast that Amgen Inc. will post 22.37 EPS for the current fiscal year.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Commission approved Amgen’s Imdylltra for extensive-stage small cell lung cancer after phase III data showed a 40% reduction in the risk of death, a meaningful catalyst that could boost future sales and investor sentiment. EC approval for Amgen’s Imdylltra
• Positive Sentiment: Multiple follow-up reports highlighted the same EU approval, reinforcing the market’s view that Amgen is adding a potentially important growth driver to its oncology portfolio. Amgen Secures EU Nod for Imdylltra in Lung Cancer Indication
• Neutral Sentiment: Zacks also pointed to Amgen as a strong momentum stock, which supports the bullish technical narrative but does not add a new business-specific catalyst. Here’s Why Amgen (AMGN) is a Strong Momentum Stock
• Neutral Sentiment: Analyst commentary on Amgen’s valuation suggests some upside remains, but it also notes that recent gains may already reflect much of the optimism, creating a more balanced long-term view. How The Amgen (AMGN) Story Is Evolving As Rare Disease Upside Meets Valuation Caution

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AMGN. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research report on Wednesday, April 8th. Piper Sandler reduced their price target on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. Daiwa Securities Group reduced their price target on shares of Amgen from $410.00 to $390.00 and set an “outperform” rating for the company in a research report on Wednesday, May 13th. UBS Group increased their price target on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Finally, Rothschild & Co Redburn increased their price target on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Amgen currently has a consensus rating of “Hold” and an average price target of $355.19.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.